Calidi Biotherapeutics CLDI Income Statement (2021-2026)

NYSE CLDI
$0.67 -0.01 (-1.98%)
As of: Nov 11, 2026 · 2:54 PM EST
Reported Financials

Calidi Biotherapeutics Quarterly Income Statement

Periods 21 quarters
Latest Jun 2026

Calidi Biotherapeutics reported net income of -$4.16M for the quarter ended Jun 2026. This income statement covers 21 quarters of results from Jun 2021 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income StatementIncome Statement Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Revenue & cost
Revenue
-0.02M-0.15M2.20M-0.22M-0.16M-0.16M-0.17M-0.13M-0.11M-0.04M-0.02M-0.01M-0.01M
Operating items
Amortization - Intangibles
-0.02M
Depreciation & Amortization - TotalDep. & Amort. (Tot)
0.10M0.10M0.10M0.09M0.10M0.11M0.09M0.09M0.09M
Research & DevelopmentR&D
1.95M2.26M2.62M3.18M3.25M3.96M2.74M2.17M2.15M1.82M2.43M2.59M2.36M2.36M2.59M2.56M
Selling, General & AdministrativeSG&A
5.04M2.43M2.79M3.36M3.97M5.86M4.01M3.61M3.07M2.21M2.64M3.07M2.69M2.11M1.60M1.59M
Other Operating ExpensesOther Opex
1.09M0.53M0.36M-0.10M-0.10M-0.10M-0.09M-0.10M-0.11M-0.09M-0.09M-0.09M
Operating ExpensesOpex
1.09M0.53M0.36M6.99M4.69M5.41M6.54M7.22M9.82M6.75M5.77M5.23M4.03M5.06M5.66M5.05M4.47M4.19M4.15M
Operating IncomeOp. Inc
-1.09M-0.53M-0.36M-6.99M-4.69M-5.41M-6.54M-7.22M-9.82M-6.75M-5.77M-5.23M-4.03M-5.06M-5.66M-5.05M-4.47M-4.19M-4.15M
Non-operating items
Non Operating Interest Expenses
0.03M0.10M0.20M0.31M0.30M0.30M0.30M0.27M0.23M0.18M0.07M0.05M0.04M0.04M0.04M0.04M
Gains (Losses) on Sale of Assets & InvestmentsGains on Sales
423.000.00M0.03M0.01M
Interest & Investment IncomeInt & Inv Inc
0.02M0.16M1.09M0.36M0.43M0.49M
Other Non Operating IncomeOther Non Op Inc.
-0.28M-2.09M-4.03M0.00M-0.01M-0.01M-0.02M-0.01M-0.02M-0.02M0.01M0.01M0.01M-0.01M-0.02M0.02M0.12M0.07M0.03M
Non Operating IncomeNon Op. Inc.
0.27M1.99M4.52M1.63M-3.07M-1.04M-5.96M5.21M1.59M-0.47M0.01M0.16M-0.12M0.00M-0.09M-0.12M0.41M0.08M-0.01M
Net income details
EBIT
-1.09M-0.53M-0.36M-6.99M-4.69M-5.41M-6.54M-7.22M-9.82M-6.75M-5.77M-5.23M-4.03M-5.06M-5.66M-5.05M-4.47M-4.19M-4.15M
EBT
-0.82M1.46M4.16M-5.35M-7.76M-6.46M-12.50M-2.01M-8.23M-7.22M-5.76M-5.07M-4.15M-5.06M-5.76M-5.17M-4.06M-4.10M-4.16M
Tax ProvisionsTaxes
0.00M0.00M0.00M0.00M0.01M0.00M0.00M0.01M0.00M0.00M0.00M0.00M0.01M0.00M0.00M0.01M
Income After Tax
-0.82M1.46M4.16M-5.36M-7.76M-6.46M-12.50M-2.02M-8.23M-7.23M-5.77M-5.07M-4.15M-5.06M-5.76M-5.18M-4.06M-4.11M-4.16M
Income from Continuing OperationsIncome (Continuing)
-0.82M1.46M4.16M-5.36M-7.76M-6.46M-12.50M-2.02M-8.23M-7.23M-5.77M-5.07M-4.15M-5.06M-5.76M-5.18M-4.06M-4.11M-4.16M
Consolidated Net IncomeConsol Net Inc.
-0.91M1.46M4.16M-5.36M-7.76M-6.46M-12.50M-2.02M-8.23M-7.23M-5.77M-5.07M-4.15M-5.06M-5.76M-5.18M-4.06M-4.11M-4.16M
Net Income Attributable to Noncontrolling InterestsNCI Net Income
-0.02M-0.05M-0.08M-0.05M-0.03M0.00M
Income towards Parent CompanyParent Net Inc
-0.82M-7.74M-4.58M-5.36M-7.76M-6.46M-12.50M-2.02M-8.23M-7.23M-5.77M-5.05M-4.10M-4.99M-5.72M-5.15M-4.06M-4.11M-4.16M
Preferred Dividend PaymentsPref Dividends
20.14M
Net Income towards Common StockholdersNet Income
-20.97M-7.74M-4.58M-5.36M-7.76M-6.46M-12.50M-2.02M-8.23M-7.23M-7.44M-5.05M-4.10M-4.99M-5.72M-10.82M-4.06M-4.42M-4.16M
Additional items
EPS (Basic)
-0.01M-646.13-382.00-495.65-842.59-628.050.00M-271.57-935.65-390.22-268.05-124.03-98.27-35.34-31.78-35.29-15.09-6.86-2.94
EPS (Diluted)
0.00M-646.13-382.00-495.65-842.59-628.050.00M-271.57-935.65-390.22-268.05-124.03-98.27-35.34-31.78-35.29-15.09-6.86-2.94
Shares Outstanding
0.00M0.02M0.01M0.01M0.01M0.01M0.01M0.00M0.01M0.01M0.02M0.03M0.04M0.04M0.14M0.18M0.31M0.27M0.64M1.42M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
0.01M0.00M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.02M0.03M0.04M0.04M0.14M0.18M0.31M0.27M0.64M1.42M
Shares Outstanding (Entity)Shares Outstanding (Entity.)
0.02M0.02M0.02M0.02M0.02M0.02M0.01M0.01M0.01M0.01M0.02M0.03M0.05M0.04M0.17M0.18M0.31M0.27M0.74M1.42M
EBITDA
-6.89M-4.47M-5.11M-6.42M-6.92M-10.00M-6.63M-5.66M-5.12M-3.63M-4.67M-5.56M-4.95M-4.04M-3.76M-4.05M
Interest ExpensesInt Expense
0.03M0.10M0.20M0.31M0.30M0.30M0.30M0.27M0.23M0.18M0.07M0.05M0.04M0.04M0.04M0.04M

Calidi Biotherapeutics Income Statement API

Pull Calidi Biotherapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=CLDI&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY